Shimadzu Europe
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
Clinical Laboratory int.
  • Allergies
  • Cardiac
  • Gastrointestinal
  • Hematology
  • Microbiology
  • Microscopy & Imaging
  • Molecular Diagnostics
  • Pathology & Histology
  • Protein Analysis
  • Rapid Tests
  • Therapeutic Drug Monitoring
  • Tumour Markers
  • Urine Analysis

Archive for category: E-News

E-News

Screenshot 2023 03 22 at 15.58.00 1

INTEGRA Biosciences’ products offer flexibility in the post-pandemic era

, 27 March 2023/in E-News /by panglobal

Many laboratories purchased pipetting solutions from INTEGRA Biosciences during the COVID-19 pandemic, to help them cope with the high numbers of samples they were receiving every day for PCR testing. Now the pandemic has been brought somewhat under control, labs are once again able to concentrate their efforts on other vital work, but what has […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/03/Screenshot-2023-03-22-at-15.58.00-1-e1680865196985.png 400 600 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-03-27 09:00:442023-03-24 11:01:59INTEGRA Biosciences’ products offer flexibility in the post-pandemic era
shutterstock 2115749144

Researchers in Japan establish novel culture system to grow HSCs in the lab

, 24 March 2023/in E-News /by panglobal

Hematopoietic stem cells (HSCs) are important immature blood cells in bone marrow that can be triggered to develop into any blood cell type. HSC transplants can be used to treat conditions where bone marrow is damaged and no longer able to produce healthy blood cells, but the widespread and safe use of HSCs is limited […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/03/shutterstock_2115749144.jpg 787 2362 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-03-24 09:47:222023-03-24 10:00:16Researchers in Japan establish novel culture system to grow HSCs in the lab
shutterstock 1662701254

‘Glow-in-the-dark’ proteins could help diagnose viral diseases

, 24 March 2023/in E-News /by panglobal

Despite recent advancements, many highly sensitive diagnostic tests for viral diseases still require complicated techniques to prepare a sample or interpret a result, making them impractical for point-of-care settings or areas with few resources. But now, a team reporting in ACS Central Science < http://pubs.acs.org/doi/abs/10.1021/acscentsci.2c01467 > has developed a sensitive method that analyzes viral nucleic […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/03/shutterstock_1662701254-scaled-e1680865285702.jpg 719 1000 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-03-24 09:44:562023-03-24 09:44:56‘Glow-in-the-dark’ proteins could help diagnose viral diseases
shutterstock 1447829285

WHO warns time running out to bring new antibiotics to market

, 24 March 2023/in E-News /by panglobal

A review from WHO on the number of new antibiotics currently in the pipeline shows that just 12 new antibiotics have entered the market in the five years from 2017-21. And there are far too few (just 27) under development in clinical trials against pathogens considered critical by WHO such as Acinetobacter baumannii and Pseudomonas […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/03/shutterstock_1447829285-scaled-e1680865325896.jpg 755 800 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-03-24 09:41:342023-03-24 09:41:34WHO warns time running out to bring new antibiotics to market
enzyme atlas

Researchers develop enzyme ‘atlas’ to help decipher cellular pathways

, 24 March 2023/in E-News /by panglobal

One of the most important classes of human enzymes are protein kinases – signalling molecules that regulate nearly all cellular activities, including growth, cell division, and metabolism. Dysfunction in these cellular pathways can lead to a variety of diseases, particularly cancer.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/03/enzyme_atlas.png 1470 1324 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-03-24 09:25:332023-03-24 09:25:33Researchers develop enzyme ‘atlas’ to help decipher cellular pathways
Owlstone logo

Owlstone partners with Bicycle Therapeutics to develop antigen-targeted EVOC Probes for early cancer detection

, 23 March 2023/in E-News /by panglobal

Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine, has entered into a Research Agreement with Bicycle Therapeutics, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/03/Owlstone-logo.png 1804 2500 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-03-23 15:10:352023-03-23 15:11:20Owlstone partners with Bicycle Therapeutics to develop antigen-targeted EVOC Probes for early cancer detection
Beckman Coulter bacteria

Beckman Coulter and MeMed to expand access to host immune response diagnostic to distinguish between bacterial and viral infections

, 23 March 2023/in E-News /by panglobal

Beckman Coulter Diagnostics, a global leader in clinical diagnostics, and MeMed, a leader in the emerging field of advanced host-response technologies, have established a strategic partnership to jointly develop and commercialize the MeMed BV test, a host immune response diagnostic that is able to distinguish between bacterial and viral infections for use on the Access […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/03/Beckman-Coulter-bacteria-e1680865390610.jpg 667 1000 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-03-23 15:08:312023-03-23 15:08:31Beckman Coulter and MeMed to expand access to host immune response diagnostic to distinguish between bacterial and viral infections
Exothera Darren Leva

Exothera appoints Darren Leva as Chief Business Officer

, 23 March 2023/in E-News /by panglobal

Exothera, a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, and oncolytic viruses, has appointed Darren Leva as Chief Business Officer. Darren’s extensive commercial experience in biotherapeutics CDMOs will further extend Exothera’s business and commercial capability across existing and brand-new markets.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/03/Exothera-Darren-Leva-scaled-e1680865410945.jpg 1000 1000 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-03-23 15:05:552023-03-23 15:05:55Exothera appoints Darren Leva as Chief Business Officer
Vetter UN compact

Vetter joins UN Global Compact Network for sustainability

, 23 March 2023/in E-News /by panglobal

Vetter has recently become a participant of the UN Global Compact Network (UN GC). Headquartered in Ravensburg, Germany, Vetter is a family-owned, global leading contract development and manufacturing organization (CDMO) with production facilities in Germany, Austria and the United States. The company has longterm experience in supporting biotechnology and pharmaceutical customers both large and small. […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/03/Vetter_UN_compact.jpg 597 500 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-03-23 14:56:272023-03-23 14:57:42Vetter joins UN Global Compact Network for sustainability
ToxTracker logo

IIVS and Toxys agree to offer ToxTracker for in vitro genetic toxicity evaluation

, 23 March 2023/in E-News /by panglobal

The Institute for In Vitro Sciences (IIVS) and Toxys have entered into a license agreement that allows IIVS to offer the ToxTracker assay. ToxTracker is an innovative in vitro assay allowing identification of the genotoxic and potentially carcinogenic properties of novel and existing drugs, (agro)chemicals, cosmetics and other substances without the use of animal testing.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/03/ToxTracker-logo.png 500 1000 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-03-23 14:53:012023-03-23 14:53:01IIVS and Toxys agree to offer ToxTracker for in vitro genetic toxicity evaluation
Page 40 of 227«‹3839404142›»
Bio-Rad - Preparing for a Stress-free QC Audit

Latest issue of Clinical laboratory

November 2025

CLi Cover nov 2025
12 December 2025

Johnson & Johnson acquires Halda Therapeutics for $3.05 billion

11 December 2025

New AlphaSync database ensures protein structure predictions stay current

11 December 2025

NADMED launches $30,000 metabolomics competition

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
clinlab logo blackbg 1

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Subscribe now!

Become a reader.

Free subscription